Antibiotic Resistances and Molecular Characteristics of Clostridioides difficile in ICUs in a Teaching Hospital From Central South China

Xiujuan Meng†, Xun Huang†, Zhong Peng‡, Yaowang Wang†, Sidi Liu†, Cui Zeng†, Juping Duan†, Ximao Wen†, Chenchao Fu†, Anhua Wu†,3* and Chunhui Li†,3*

†Infection Control Center, Xiangya Hospital of Central South University, Changsha, China; ‡State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China; §National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of Central South University, Changsha, China

Clostridioides (C.) difficile is a major healthcare-associated pathogen inducing infectious diarrhea. Approximately 25–33% of patients with antibiotic-associated diarrhea (AAD) and 90% of patients with pseudomembranous enteritis are caused by C. difficile infection (CDI). Stool samples were collected from hospitalized adults with presumptive AAD in four nonneonatal intensive care units (ICUs). Diagnosis of CDI was based on both clinical symptoms and laboratory results. The stool specimens were transferred onto CDIF (C. difficile agar), and C. difficile was finally confirmed by the latex agglutination test. Toxin-producing genes tcdA (A), tcdB (B), and cdt (CDT) were detected by PCR, and all isolates were performed multilocus sequence typing analysis. The antibiotic susceptibility of C. difficile isolates was assessed by the agar dilution method. A total of 184 C. difficile were isolated from 857 specimens in our study, the isolation rate of C. difficile was 21.5% (184/857). The 184 C. difficile isolates were isolated from 179 patients, among these 115 patients were toxin-positive, giving the incidence of CDI being 58.0/10,000 patient days in the four ICUs. Among these 115 toxin-positive C. difficile isolates, 100 (87.0%) isolates produced two toxins (A+B+CDT-), three (2.6%) isolates were A+B+ with binary toxin-producing (A+B+CDT+), and 12 (10.4%) isolates only produced one toxin (A-B+CDT-). A total of 27 sequencing types (STs) were obtained. The most prevalent was ST3 (34 isolates), followed by ST39 (27 isolates), ST54 (19 isolates), ST26 (16 isolates), ST35 (15 isolates), and ST2 (13 isolates). All the ST26 isolates were nontoxigenic. Meanwhile, five STs were newly discovered. Although multidrug resistance was present in ≥50% of these C. difficile isolates, all of them were susceptible to tigecycline, fidaxomicin, metronidazole, and vancomycin. In conclusion, C. difficile isolates producing two toxins (A+B+CDT-) were dominant in our hospital. The most prevalent was ST3, and all ST26 isolates were NTCD. Although multidrug resistance was present in ≥50% of the C. difficile isolates, metronidazole, tigecycline, fidaxomicin, and vancomycin were still effective treatments for CDI in our hospital.

Keywords: Clostridioides difficile, Clostridioides difficile infection, antibiotic resistance, molecular characteristics, ICUs, Central South China
INTRODUCTION

Clostridioides difficile is a major healthcare-associated pathogen inducing infectious diarrhea, which is responsible for a wide spectrum of diseases, ranging from mild diarrhea to fulminant colitis and even death (1). Approximately 25–33% of patients with antibiotic-associated diarrhea and 90% of patients with pseudomembranous enteritis are due to C. difficile colitis and even death (2). The CDI has been associated with increased morbidity and decreased quality of life in patients, accompanied by prolonged hospitalization (3–5).

Recently, the incidence of CDI has been reported to increase in various countries. Sweden, China, and several other countries have reported an incidence rate of 17.1/10,000 admission to hospitals (6). The incidence of CDI has largely increased due to the emergence of an epidemic ribotype (sequence type [ST]: 1/027/NAP1), and the development of more sensitive detection approaches (7). CDI has been recognized to initiate from unusual antibiotic exposure of intestinal microbiota. The most important risk factor for CDI is broad-spectrum antimicrobial drugs that induce intestinal microfloral dysbiosis (8).

The severity and consequences of CDI are influenced by multiple factors, namely, hypervirulent isolates, age, immune status, and underlying conditions of the patient (e.g., receipt of antimicrobial therapy) (9). A novel C. difficile isolate with binary toxin-positive (non-027, non-078), associated with severe diarrhea has been recently reported in our hospital (10). Furthermore, the emergence of resistance to antimicrobial agents has complicated the treatment for CDI patients (11). Therefore, exploring the prevalence of antimicrobial-resistant C. difficile in an institution can facilitate optimizing antimicrobial stewardship programs. In this study, important information on the incidence of CDI was provided, and antibiotic resistance of C. difficile among patients in intensive care units (ICUs) wards was conducted.

MATERIALS AND METHODS

Study Location and Population

A prospective study was performed to monitor patients from April 2017 to November 2017, identifying cases of hospital-onset diarrhea in four nonneonatal ICUs in Xiangya Hospital, which is a 3,500-bed tertiary university hospital in Changsha, Hunan Province, China, with approximately 100,000 annual admissions. The four nonneonatal ICUs include general ICU (GICU, 35 beds), neurosurgery ICU (NSICU, 20 beds), neurology ICU (NICU, 16 beds), and respiratory ICU (RICU, 10 beds). This study was approved by the Ethics Committee of Xiangya Hospital.

Inclusion and Exclusion Criteria

Inclusion Criteria

Hospitalized patients aged ≥ 18 years old; diarrhea after 48 h following admission to the hospital; antibiotics administered before the occurrence of diarrhea (irregular stools ≥ 3 times per day with the Bristol grade as 5–7).

Exclusion Criteria

Hospitalized patients aged < 18 years old; diarrhea within 48 h after admission to the hospital; irregular-shaped stools < 3 times per day; patients with diarrhea diagnosed as gastrointestinal infection or intestinal functional diseases.

Isolation of C. difficile and CDI Diagnosis

Stool specimen was collected from the patients with diarrhea occurring ≥ 48 h after admission and before discharge, and specimen (about 1 g) was taken and placed in 1 ml of sterile saline and mixed well, then transferred onto CDIF agar (Chrome ID C. difficile) (Biomerieux, Shanghai, China) and incubated in anaerobic airtight containers (Biomerieux, Shanghai, China) for ≥ 48 h. C. difficile isolates were identified by odor and colony morphology, followed by final confirmation with latex agglutination test using glutamate dehydrogenase (Biomerieux, Shanghai, China) and PRO DISK (Remel, England).

The 16S rDNA and toxin-producing genes tcdA, tcdB, cdtA, and cdtB were conducted by PCR according to prior recommendations (12). 16S rDNA was an internal positive control in toxin gene PCR. The patients with stool cultured positive for C. difficile, meanwhile, the isolates that tested positive for toxin gene by PCR were diagnosed with CDI.

MLST Analysis of C. difficile

Multilocus sequence typing (MLST) was performed to analyze the C. difficile isolates (both toxigenic and nontoxigenic) following a previously established method (13). The genomic DNA was obtained from C. difficile cultured on blood agar (BioMerieux, Shanghai, China) for 48 h at 37°C under anaerobic conditions. High molecular weight DNA extracted using QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, USA) according to the instructions of the manufacturer. The specimen was coded with a unique study ID, collection dates, test results, and the data of the patient were registered.

Determination of Antibiotic Resistance

The susceptibility of C. difficile isolates to 11 types of antibiotics, namely, chloramphenicol (CHL), metronidazole (MTZ), vancomycin (VAN), rifaximin (RFX), fidaxomicin (FDX), ampicillin (AMP), clindamycin (CLI), tigecycline, fusidic acid (FSA), levofloxacin (LVX), and tetracycline (TE) were tested by agar dilution according to the procedures of the Clinical and Laboratory Standards Institute (CLSI-M100-S29). The minimum inhibitory concentrations (MICs) defined as the lowest concentration of each antimicrobial agent that inhibited the growth of the tested isolate, were recorded after 48 h of incubation following CLSI recommendations. The antibiotics were purchased from MedChemExpress (America). MIC50 and MIC90 referred to the MIC required to inhibit the growth of 50% and 90% of the tested bacteria. C. difficile ATCC 70057 and Bacteroides fragilis ATCC 25285 were used for quality control. The interpretive breakpoints for CHL (MIC ≥ 32), CLI (MIC ≥ 8), TE (MIC ≥ 16), AMP (MIC ≥ 2), LVX (MIC ≥ 8), and MTZ (MIC ≥ 32) were set following the guidelines recommended by CLSI (https://clsi.org/media/1872/_m100_archived_drugs_table.pdf). The breakpoint for VAN (MIC
> 2) was based on the European Antimicrobial Susceptibility Test Committee (14). The resistance breaking points for RFX (MIC > 32) and FSA (MIC > 0.5) were according to the literature (15). No resistance breaking points were available for fidaxomicin and tigecycline with specific.

**Statistical Analysis**

Data were presented by the rate, and the comparison of antibiotic resistance rate was conducted by chi-squared test. *P* < 0.05 indicates that the difference is statistically significant.

**RESULTS**

**C. difficile Isolation and Isolation Rate**

A total of 857 specimens meeting the criteria were collected, among which 184 *C. difficile* were isolated, with an isolation rate of *C. difficile* as 21.5% (184/857). Repetitive specimens from the same patient were excluded. Among the total 774 patients with diarrhea, 179 patients were positive for *C. difficile* culture, while the other 595 patients were *C. difficile* negative (Figure 1).

**Incidence of CDI in Four ICUs**

Among the 179 patients, 115 patients (14.8%, 115/774) tested positive for toxin production and were diagnosed with CDI. Of the 115 patients, 12 patients were with A-B+CDT-, 100 patients were with A+B+CDT-, and three patients were with A+B+CDT+. The incidence of CDI in the patients from four ICUs was 58.0/10,000 patient days. Among these CDI patients, 70 patients were from GICU (82.0/10,000 patient days), 31 patients were from NICU (75.7/10,000 patient days), seven patients were from NSICU (15.3/10,000 patient days), and seven patients were from RICU (26.4/10,000 patient days). The incidence rate of CDI among four ICUs departments were shown in Table 1.

**Clinical Features and Antibiotics Exposure of CDI Patients**

The patients with CDI were mostly men (78 patients), and 39 patients were ≥ 65 years old, the common underlying diseases were hypertension, diabetes, and consciousness disorder in these patients. Among these 115 patients with CDI, 35 (30.43%) patients used two or more antibiotics in combination. Meanwhile, 32 (27.83%) patients used carbapenems, 31 (26.95%) patients used β-lactam mixture, and 29 (25.21%) patients used third and fourth generation cephalosporins. The clinical features and antibiotics exposure of CDI patients were shown in Table 2.

**MLST Analysis of C. difficile Isolates**

A total of 27 STs were identified in the above-mentioned 179 *C. difficile* strains, which were divided into four main clades. Among these STs, the most prevalent types were ST3 (34, 19.0%), followed by ST39 (27, 15.1%), ST54 (19, 10.6%), ST26 (16, 8.9%), ST35 (15, 8.4%), ST2 (13, 7.3%), ST37 (9.5.0%), ST129 (7, 3.9%), ST15 (5, 2.8%), ST83 (5, 2.8%), ST5 (3, 1.7%), ST14 (3, 1.7%), ST33 (3, 1.7%), ST476 (2, 1.1%), and one isolate for each of the other STs. All the ST26 isolates were nontoxin-producing *C. difficile*. Moreover, five STs were newly discovered, among which ST475 was obtained from SICU, ST476 was from both SICU and SGICU, while ST477, ST478, and ST479 were from GICU. Meanwhile, only one gene (tpi) was found different between ST477 and ST37 isolates. The novel ST data have been submitted to the MLST database.

**Toxin Gene Detection of C. difficile Isolates**

A total of 179 nonrepetitive *C. difficile* isolates were collected in this study, 115 isolates (64.2%, 115/179) were toxin-producing, while the rest 64 isolates (35.8%, 64/179) were nontoxigenic isolates. Among these 115 toxin-producing isolates, 100 isolates (87.0%, 100/115) were positive for the two toxin genes (tcdA and tcdB), but negative for binary toxin encoding genes (A+B+CDT-); three isolates (2.6%, 3/115) were positive for both tcdA and tcdB, and the binary toxin encoding genes (A+B+CDT-); 12 isolates (10.4%, 12/115) could produce only tcdB, but negative for tcdA and binary toxin genes (A-B+CDT-). Among the *C. difficile* isolates with two toxin genes (A+B+CDT-), three isolates (2.6%, 3/115) were positive for both tcdA and tcdB, and the binary toxin encoding genes (A+B+CDT-), which belonged to ST5 and ST3; 12 isolates (10.4%, 12/115) could produce only tcdB, but negative for tcdA and binary toxin genes (A-B+CDT-). Among the *C. difficile* isolates with two toxin genes (A+B+CDT-), ST3 and ST54 were the main ST types. *C. difficile* isolates with both two toxin genes and binary (A+B+CDT+) belonged to ST5 and ST39, and ST37 were the most common ST type in *C. difficile* isolates with only tcdB (A-B+CDT-). All the ST26 isolates in this study were nontoxigenic (NTCD). The relationship of sequence types and toxin genes of *C. difficile* isolates was shown in Figure 2.
TABLE 1 | The incidence rate of C. difficile infection among four ICUs departments.

|                | Total patients (cases) | Diarrhea patients (cases) | CD toxin-positive patients (cases) | Patient days | Incidence rate of CDI (/10,000 patient days) |
|----------------|------------------------|---------------------------|------------------------------------|--------------|---------------------------------------------|
| GICU           | 620                    | 558                       | 70                                 | 8,537        | 82.0                                        |
| NICU           | 153                    | 148                       | 31                                 | 4,095        | 75.7                                        |
| NSICU          | 40                     | 33                        | 7                                  | 4,565        | 15.3                                        |
| RICU           | 44                     | 35                        | 7                                  | 2,647        | 26.4                                        |
| Total          | 857                    | 774                       | 115                                | 19,844       | 58.0                                        |

CDI incidence calculated as C. difficile toxin-positive patients/patient days.

TABLE 2 | Clinical features and antibiotics exposure of the CDI patients.

| Variable                     | Case (n = 115) | Antibiotics exposure | Case (n = 115) |
|------------------------------|---------------|----------------------|---------------|
| Age ≥ 65 year                | 39 (33.9%)    | Two kinds and more   | 35 (30.4%)    |
| Sex, male (%)                | 78 (67.8%)    | Cefamycins           | 18 (15.7%)    |
| Diabetes                     | 23 (20.0%)    | Cephalosporin (3th and 4th) | 29 (25.2%) |
| Hypertension                 | 43 (37.4%)    | Cephalosporin (1th and 2th) | 4 (3.5%)    |
| Respiratory failure          | 8 (7.0%)      | β-lactam mixture     | 31 (26.9%)    |
| Renal insufficiency          | 10 (8.7%)     | Tigecycline          | 5 (4.4%)      |
| Cardiac insufficiency        | 12 (10.4%)    | Carbapenems          | 32 (27.8%)    |
| Tuberculosis                 | 4 (3.5%)      | Penicillins          | 25 (21.7%)    |
| Tumor                        | 11 (9.6%)     | Glycopeptides        | 10 (8.7%)     |
| Autoimmune diseases          | 3 (2.6%)      | Linezolid            | 3 (2.6%)      |
| Liver disease                | 14 (12.2%)    | Quinolones           | 14 (12.2%)    |
| Consciousness disorder       | 25 (21.7%)    | Antifungal           | 8 (7.0%)      |

50.0%) and TE (50.0 and 50.0%). Meanwhile, the resistance to LVX (47.0 and 50.0%) and FSA (44.0 and 41.7%) was also high. The MIC values of CHL (MIC90 ≥ 256 µg/ml), CLI (MIC90 ≥ 128 µg/ml), TE (MIC90 ≥ 128 µg/ml), AMP (MIC90 ≥ 128 µg/ml), and LVX (MIC90 > 128 µg/ml) were relatively high, while those of tigecycline (MIC90 = 0.25 µg/ml) and fidaxomicin (MIC90 = 0.5 µg/ml) were relatively low. Moreover, we found that all the 115 isolates were susceptible to MTZ and vancomycin.

Antibiotic Resistance Rate of C. difficile Isolates According to ST Type
A comparison of the prevalence of antibiotic resistance among different STs of the C. difficile isolates was shown in Table 4. The rates of CLI (58.3%), TE (33.3%), and AMP (50%) resistance in ST2 C. difficile isolates were lower than those in other STs. Meanwhile, the prevalence of CHL resistance was high in all STs (66.7–100%), while a great variety was observed in that of FSA (0.0–73.6%). In addition, most of the C. difficile isolates were sensitive to rifaximin (0.0–16.7%).

Antibiotic Resistance Type of Toxigenic C. difficile Isolates
Except for one C. difficile isolates was sensitive to all the seven antibacterial drugs in our study, other isolates were found to be resistant to at least one of these antibiotics, and most of them were resistant to either CHL, CLI, or AMP (Figure 3). Among these 115 toxigenic C. difficile isolates, 92 isolates (80.0%) were resistant to at least three antibiotics, and multiple resistance to CHL, CLI, TE, AMP, LVX, and FSA (20 isolates) were most common, followed by 12 isolates were resistant to four antibiotics (CHL+CLI+AMP+LVX), six isolates were resistant to another four antibiotics (CHL+CLI+AMP+LVX), and another six isolates were resistant to three antibiotics (CHL+CLI+TE). A total of 72 isolates were resistant to more than three antibiotics. Among these isolates, 32 isolates were resistant to four antibiotics, 13 isolates were resistant to five antibiotics, 22 isolates were resistant to six antibiotics, and only two isolates were resistant to the seven antibiotics.

DISCUSSION
Patients with diarrhea are not routinely tested for C. difficile in China, therefore, CDI might be underestimated (16–18). In our study, we actively tested patients in the ICU ward, the isolation rate of C. difficile was 21.5% (184/857), which is similar to the study by Polage et al. (19), in which 21.0% (293 out of 1,416) of hospitalized adults were tested C. difficile positive by PCR. However, another study with an immunochromatographic test reported a 4.9% positive rate among the patients with diarrhea (20), which is much lower than our results. The difference might be due to the limitations and methods of the studies, or might be related to the size of the study population. Moreover, the ICU patients in our study almost received broad-spectrum
FIGURE 2 | The relationship of sequence types and toxin genes of \( C. \) difficile isolates.

TABLE 3 | The antibiotic resistance of \( C. \) difficile isolates according to toxin type.

| tcdA\(^+\) tcdB\(-\)ctdA-ctdB-(\(n = 100\) isolates) | tcdA\(-\) tcdB\(+\)ctdA-ctdB-(\(n = 12\) isolates) | \( P \) value |
|---|---|---|
| **Range** | **MIC 50** | **MIC 90** | **Resistance rate (%)** | **Range** | **MIC 50** | **MIC 90** | **Resistance rate (%)** | **Range** | **MIC 50** | **MIC 90** | **Resistance rate (%)** | **Range** | **MIC 50** | **MIC 90** | **Resistance rate (%)** |
| MTZ | 0.125–0.5 | 0.25 | 0.25 | 0 | 0.125–0.5 | 0.25 | 0.25 | 0 | - | - |
| VAN | 0.125–2 | 0.5 | 1 | 0 | 0.125–1 | 0.5 | 1 | 0 | - | - |
| TGC | 0.125–0.5 | 0.25 | 0.25 | - | 0.125–0.25 | 0.25 | 0.25 | - | - | - |
| CLI | 0.125–256 | 32 | 128 | 81.0 | 0.5–256 | 64 | 128 | 91.2 | 0.36 | - |
| CHL | 0.25–256 | 256 | 256 | 89.0 | 4–256 | 256 | 256 | 91.2 | 0.78 | - |
| TE | 0.125–256 | 16 | 256 | 50.0 | 0.25–256 | 4 | 128 | 50.0 | 1.00 | - |
| AMP | 0.25–256 | 2 | 128 | 68.0 | 0.25–256 | 2 | 128 | 50.0 | 0.21 | - |
| LVX | 0.25–256 | 4 | 256 | 47.0 | 0.25–256 | 4 | 128 | 50.0 | 0.84 | - |
| RFX | 0.125–256 | 0.25 | 8 | 5.0 | 0.25–128 | 0.25 | 0.25 | 16.7 | 0.12 | - |
| FSA | 0.125–64 | 0.25 | 0.5 | - | 0.25–8 | 0.25 | 2 | 41.7 | 0.87 | - |
| FDX | 0.125–0.5 | 0.25 | 0.5 | - | 0.125–0.5 | 0.25 | 0.5 | - | - | - |

antibiotics, which might have potentially induced the emergence of CDI (21).

The positive rate (14.8%, 115/774) of \( C. \) difficile toxin genes in this study is higher than our previous study (8%, 47/593) (9). The overall incidence rate of CDI (58.0/10,000 patient days) is also higher than our previous study (14.1/10,000 patient days) (4), and the highest incidence of CDI was found in GICU patients (82.0/10,000 patient days). This might be due to the wide administration of broad-spectrum antibiotics in recent years. In our study, among these 115 patients with CDI, 35 patients used two or more antibiotics in combination. Meanwhile, 32 patients used carbapenems, 31 patients used \( \beta \)-lactam mixture. In addition, the higher positive rate might be related to the use of the chromogenic medium, which could better detect \( C. \) difficile. A study by 17 hospitals in South Korea found that the CDI incidence increased from 17.0/100,000 adult inpatients in 2004 to 27.0/100,000 adult inpatients in 2008 (22). Moreover, the incidence rate reported in the United States during the same period was 87.5/100,000 hospitalized patients (23). The reasons for the
increased incidence rate might be related to the advanced detection approaches.

Although A+B+ (87.0%) was the dominant C. difficile toxigenic type found in this study, the prevalence of A-B+ has been reported to increase in several other regions of the world (24). We found that only 12 (10.4%) isolates produce only one toxin (A-B+CDT-), which is lower than what has been reported previously in Beijing (23.3%) (17). Interestingly, infection with toxin-positive C. difficile isolates has been associated with higher mortality and recurrence rates (25). In this study, three (2.6%) isolates of C. difficile were positive for both the two toxin genes and binary toxin gene (A+B+CDT+), which is similar to that reported by another study in Shanghai (1.6%) (26). However, the overall prevalence of A+B+ C. difficile isolates in China is much lower than that in North America and Europe (27). Global variability in the prevalence of C. difficile strains with A+B+ could be due to the differences in testing methods, patient-related factors, surveillance sensitivity, and differential
infection control practices and distribution of toxigenic C. difficile isolates (9).

Based on the MLST analysis, a total of 27 C. difficile STs were identified, which were divided into four main clades. The most common four STs (ST3, ST39, ST54, and ST26) were different from our previous study (9). Our previous study on CDI among patients with hospital-acquired pneumonia showed that the predominant STs of C. difficile were ST54 (20%), ST37 (15.6%), and ST3 (9.4%) (4). This might be related to the clonal spread of C. difficile isolates in the hospital. ST3 and ST54 were the main ST types in C. difficile isolates with tcdA-positive and tcdB-positive (A+B+CDT-). ST37 was the most common ST type in C. difficile isolates with only tcdB-positive (A-B+CDT-).

In another study, ST54 was the most common ST type in C. difficile isolates with two toxin genes (tcdA+, tcdB+, cdtA-) (28). Meanwhile, ST37 belonged to C. difficile isolates with only tcdB-positive (A-B+CDT-) in another study in China (29). C. difficile isolates with binary (A+B+CDT+) belonging to ST5 and ST39. All the ST26 strains in this study were NTCD, which is supported by Couturier et al. (30).

Among these 115 toxigenic C. difficile isolates, 92 strains (80.0%) were resistant to at least three antibiotics, and multiple resistance to CHL, CLI, TE, AMP, LVX, and FSA (20 strains) were most common, followed by 12 strains were resistant to four antibiotics (CHL+CLI+AMP+FSA) (Figure 3). High-level resistance to AMP, CHL, CLI, and LVX was detected among the isolates with A-B+ and A+B+ in this study. The rates of CLI, TE, and AMP resistance among ST2 C. difficile isolates were lower than those in other STs. Previous data showed that resistance to CLI (8.3–100%), cephalosporins (51%), erythromycin (13–100%), and fluoroquinolones (47%) is commonly observed in C. difficile isolates within the past 15 years (2000–15) (31). Similar antibiotic resistance was also found in the C. difficile isolates investigated in this study. These data in our study suggest that antibiotic resistance of C. difficile remains prevailing. More worrisome, most of the C. difficile isolates investigated in this study showed resistance to multiple antibiotics.

Although several studies have reported the increasing MICs for MTZ and vancomycin in C. difficile, all isolates in the current study were susceptible to these two antibiotics. Both MTZ and vancomycin are the most commonly used antibiotics for mild-to-moderate and severe CDI (32), and they have been used for more than 30 years. In a multicenter study conducted in Taiwan, all C. difficile isolates were susceptible to MTZ, however, two isolates had reduced susceptibility to vancomycin (MIC = 4 µg/ml) (33). Furthermore, the MICs of tigecycline and fidaxomicin were low in our study. Fidaxomicin is associated with a significantly lower recurrence rate in CDI therapy, therefore, it is considered to have similar therapeutic efficacy as oral vancomycin (8, 12). In addition to vancomycin, MTZ, and fidaxomicin, tigecycline has been used in cases where severe adverse effects occurred following standard therapy (3-4). Although C. difficile isolates are resistant to multiple antibiotics in our study, antimicrobial therapy is still the first choice for CDI, and specific guideline recommendations of antimicrobial therapy should be based on the severity of the CDI.

CONCLUSIONS

In conclusion, C. difficile isolates from CDI patients in our hospital are dominated by those producing two toxins (A+B+CDT-). ST3 isolates are the most prevalent ST, and ST26 isolates are all NTCD. The higher positive rate of C. difficile might be due to the wide administration of broad-spectrum antibiotics in recent years. Although multidrug resistance is present in ≥50% of the C. difficile isolates, MTZ and vancomycin are still effective against C. difficile, serving as available treatment options for CDI patients.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

Conceptualization and methodology by XM, XH, and AW. Software and formal analysis by ZP and CF. Data collection by CZ, YW, SL, and JD. Writing-original draft preparation by XM. Writing-review and editing by XM, CL, and AW. Funding acquisition by CL and AW. All authors have read and agreed to the published version of the manuscript.

FUNDING

This work was supported by the Key Research and Development Projects of Hunan Province (Nos. 2020SK3027 and 2020SK3028) and Natural Science funding of Hunan Province (No. 2021JJ31071).

REFERENCES

1. Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N Engl J Med. (2008) 359:1932–40. doi: 10.1056/NEJMra0707500
2. Evans CT, Safdar N. Current trends in the epidemiology and outcomes of clostridium difficile infection. Clin Infect Dis. (2015) 60 Suppl 2:S66–71. doi: 10.1093/cid/civ140
3. Del PR, Ronga L, Addati G, Magrone R, Abbasciano A, Decimo M, et al. Clostridium difficile. A review on an emerging infection. Clin Ter. (2019) 170:e41–7. doi: 10.7417/CT.2019.2106
4. Li C, Duan J, Liu S, Meng X, Fu C, Zeng C, et al. Assessing the risk and disease burden of Clostridium difficile infection among patients with hospital-acquired pneumonia at a University Hospital in Central China. Infection. (2017) 45:621–8. doi: 10.1007/s10795-017-1024-1
5. Czepiel J, Krutova M, Mizrahi A, Khanafer N, Enoch DA, Patyi M, et al. Mortality Following Clostridiodises difficile Infection in Europe: A Retrospective Multicenter Case-Control Study. Antibiotics (Basel). (2021) 10:299. doi: 10.3390/antibiotics10030299
6. Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, et al. Molecular and clinical characteristics of Clostridium difficile infection in a
University Hospital in Shanghai, China. *Clin Infect Dis.* (2008) 47:1606–8. doi: 10.1086/593365

7. Gould CV, Edwards JR, Cohen J, Bamberg WM, Clark LA, Farley MM, et al. Effect of nucleic acid amplification testing on population-based incidence rates of *Clostridium difficile* infection. *Clin Infect Dis.* (2013) 57:1304–7. doi: 10.1093/cid/cit922

8. Gerding DN, File TJ, McDonald LC. Diagnosis and treatment of *clostridium difficile* infection (CDI). *Infect Dis Clin Pract (Baltim Md)*. (2016) 24:3–10. doi: 10.1097/IPC.0000000000000350

9. Li C, Li Y, Huai Y, Liu S, Meng X, Duan J, et al. Incidence and outbreak of healthcare-onset healthcare-associated *clostridium difficile* infections among intensive care patients in a large teaching hospital in China. *Front Microbiol.* (2018) 9:566. doi: 10.3389/fmicb.2018.00586

10. Li C, Liu S, Zhou P, Duan J, Dou Q, Zhang R, et al. Emergence of a novel binary toxin-positive strain of *clostridium difficile* associated with severe diarrhea that was not ribotype 027 and 078 in China. *Infect Control Hosp Epidemiol.* (2015) 36:1112–4. doi: 10.1017/ice.2015.120

11. Gil F, Calderon IL, Fuentes JA, Paredes-Sabja D. *Clostridioides* (*Clostridium*) difficile infection: current and alternative therapeutic strategies. *Future Microbiol.* (2018) 13:469–82. doi: 10.2217/fmb-2017-0203

12. Peng Z, Addisu A, Alraba S, Sun X. Antibiotic resistance and toxin production of *clostridium difficile* strains isolated from the hospitalized patients in a large hospital in Florida. *Front Microbiol.* (2017) 8:2584. doi: 10.3389/fmicb.2017.02584

13. Griffiths D, Fawley W, Kachrimanidou M, Bowden R, Crook DW, Fung R, et al. Multilocus sequence typing of *clostridium difficile*. *J Clin Microbiol.* (2010) 48:770–8. doi: 10.1128/JCM.01796-09

14. EUCAST. Available online at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf.

15. EUCAST. Available online: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf.

16. Cheng JW, Xiao M, Kudinha T, Xu ZP, Hou X, Sun LY, et al. The first two *clostridium difficile* ribotype 027/ST1 isolates identified in Beijing, china-an emerging problem or a neglected threat? *Sci Rep.* (2016) 6:18834. doi: 10.1038/srep18834

17. Cheng JW, Xiao M, Kudinha T, Kong F, Xu ZP, Sun LY, et al. Molecular epidemiology and antimicrobial susceptibility of *clostridioides difficile* isolates from a university teaching hospital in China. *Front Microbiol.* (2016) 7:1621. doi: 10.3389/fmicb.2016.01621

18. Li C, Ren N, Zhou P, Huang X, Gong R, et al. Point-prevalence study of healthcare-associated *clostridioides difficile* infections among intensive care patients in a large teaching hospital in China. *Epidemiol Infect.* (2013) 141:189–94. doi: 10.1017/S0950268812000581

19. Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, et al. *Clostridioides difficile* resistance to antimicrobial agents, namely, fidaxomicin (OPT-80) and rifaximin: a molecular epidemiology study. *Epidemiol Infect.* (2013) 141:189–94. doi: 10.1017/S0950268812000581

20. Hematyar Y, Pirzadeh T, Moaddab SR, Ahangarzadeh RM, Memar Nordi, et al. Emergence of a novel binary toxin-positive strain of *clostridium difficile* associated with severe diarrhea that was not ribotype 027 and 078 in China. *Infect Control Hosp Epidemiol.* (2015) 36:1112–4. doi: 10.1017/ice.2015.120

21. Spigaglia P, Mastrantonio P, Barbanti F. Antibiotic resistances of *clostridium difficile*. *Adv Exp Med Biol.* (2018) 1050:137–59. doi: 10.1007/978-3-319-72799-8_9

22. Kim YS, Han DS, Kim YH, Kim WH, Kim JS, Kim HS, et al. Incidence and clinical features of *clostridium difficile* infection in Korea: a nationwide study. *Epidemiol Infect.* (2013) 141:189–94. doi: 10.1017/S0950268812000581

23. Lucado J, Gould C, Elihauser A. *Clostridium difficile* Infections (CDI) in Hospital Stays, 2009. HCUP Statistical Brief #124. Rockville, MD: Agency for Healthcare Research and Quality. (2012) 11:75–9. Available online at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf

24. King AM, Mackin KE, Lyras D. Emergence of toxin A-negative, toxin B-positive *clostridium difficile* strains: epidemiological and clinical considerations. *Future Microbiol.* (2015) 10:1–4. doi: 10.2217/fmb.14.115

25. Stewart DB, Berg A, Hegarty J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. *J Gastrointest Surg.* (2013) 17:118–124, 124–125. doi: 10.1007/s11605-012-2056-6

26. Huang H, Weintraub A, Fang H, Wu S, Zhang Y, Nord CE. Antimicrobial susceptibility and heteroresistance in Chinese *Clostridium difficile* strain. *Anastase.* (2010) 16:633–5. doi: 10.1016/j.anastase.2010.09.002

27. Bassetti M, Villa G, Pecori D, Arzese A, Wilcox M. Epidemiology, diagnosis and treatment of *Clostridium difficile* infection. *Expert Rev Anti Infect Ther.* (2012) 10:1405–23. doi: 10.1586/eri.12.135

28. Shouei P, Shoiaei H, Khorvash F, M H S, Ataei B, Esfandiari Z, Vakili B, Rozati M, Safavi AA: *Clostridium difficile* infection in cancer patients with hospital acquired diarrhea at the teaching hospitals in Iran: Multilocus sequence typing analysis (MLST) and Antimicrobial resistance pattern. *Ann. (2019) 31:365–73. doi: 10.7416/ai.2019.2298

29. Cheng JW, Liu C, Kudinha T, Xiao M, Yu SY, Yang CX, et al. Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry to identify MLST clade 4 *Clostridium difficile* isolates. *Diagn Microbiol Infect Dis.* (2018) 92:19–24. doi: 10.1016/j.diagmicrobio.2018.04.011

30. Couturier J, Franconeri L, Jancois N, Gigot P, Rousset A, et al. Characterization of non-toxigenic *clostridioides difficile* strains isolated from preterm neonates and in vivo study of their protective effect. *J Clin Med.* (2020) 9:3650. doi: 10.3390/jcm9113650

31. Spigaglia P. Recent advances in the understanding of antibiotic resistance in *Clostridium difficile* infection. *Ther Adv Infect Dis.* (2016) 3:23–42. doi: 10.1177/20499361156122891

32. Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. *JAMA.* (2016) 316:1193–204. doi: 10.1001/jama.2016.11764

33. Liao CH, Ko WC, Lu JJ, Hsueh PR. Characterization of clinical isolates of *clostridium difficile* by toxin genotypes and by susceptibility to 12 antimicrobial agents, namely, fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. *Antimicrob Agents Chemother.* (2012) 56:3943–9. doi: 10.1128/AAC.00191-12

34. Facciornuza A. *Clostridium difficile* infection. *N Engl J Med.* (2015) 373:286–7. doi: 10.1056/NEJMct1506004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Meng, Huang, Peng, Wang, Liu, Zeng, Duan, Wen, Fu, Wu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.